Intravenous Infusions PLC has appointed investment and finance executive Kojo Nketia Appenteng to its Board of Directors, adding more than 25 years of international experience in investment banking, private equity, strategic advisory and healthcare-sector leadership.

Mr Appenteng will serve on the company’s Finance Committee and Technical Committee. In these roles, he is expected to work with the board and management team on the execution of Intravenous Infusions’ strategy, capital planning, financial performance, operational priorities and growth initiatives.

His appointment brings extensive transaction and corporate finance experience to the Ghanaian pharmaceutical manufacturer. Over his career, Mr Appenteng has led and executed more than US$40 billion in mergers and acquisitions, public offerings, recapitalisations and other strategic transactions across North America, the United Kingdom, continental Europe and Sub-Saharan Africa.

He is the co-founder and Managing Partner of New York-based investment and advisory firm Catrana Capital, where he focuses on growth-oriented businesses. His responsibilities include private equity investment evaluation, transaction structuring, capital raising, investor engagement and value-creation strategies.

Before establishing Catrana Capital, Mr Appenteng was a Managing Director at Stifel, Nicolaus & Co. in New York, where he led the firm’s global healthcare technology investment banking practice. He previously held senior investment banking positions at Credit Suisse, Harris Williams and Morgan Stanley and also served as Chief Financial Officer of MoveMedical.

His professional experience covers healthcare, pharmaceuticals, medical products and technology-enabled businesses. According to the company’s announcement, he has led major healthcare technology transactions, supported the rapid transformation of a multinational healthcare company and helped build a top-three healthcare technology investment banking franchise in the United States.

Intravenous Infusions said his international experience would support its efforts to strengthen domestic pharmaceutical manufacturing, widen access to essential medical products and build a leading healthcare platform in Ghana and the wider region.

Mr Appenteng also serves as a Director of CCM Healthcare Investments – FZCO and as a board member of The PAR Fund. He previously held board roles with Accion’s Center for Financial Inclusion and Seeding Labs.

He holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science with honours in Computer Science from Bowling Green State University, where he graduated as valedictorian. He is also an alumnus of the Impact Investing Programme at the University of Oxford’s Saïd Business School.

The appointment strengthens Intravenous Infusions’ board with expertise in finance, healthcare investment, capital raising and strategic transactions as the company pursues its operational and regional growth plans.